In clinical studies to-date (proof of concept, pharmacokinetics and safety), cenicriviroc (CVC) has been shown to suppress viral load, reduce inflammation biomarkers, and have a good pharmacokinetic (PK), safety and tolerability profile.
-
In a Phase 2a clinical study, individuals treated with CVC monotherapy (once a day for 10 days) experienced a median nadir decline in HIV viral load of up to 1.8 log10 copies/mL compared to baseline.
-
In the same Phase 2a study, treatment with CVC was shown to increase concentrations of monocyte chemoattractant protein 1 (MCP-1), a marker of inflammation. This finding confirmed the potent inhibition of CCR2.
The following links will take you to clinical data presentations as well as to peer-reviewed journal publications:
